期刊
THERANOSTICS
卷 12, 期 7, 页码 3628-3636出版社
IVYSPRING INT PUBL
DOI: 10.7150/thno.71761
关键词
Tumor-on-a-chip; tumor microenvironment; cancer immunotherapy; personalized therapy
资金
- Indiana University Bloomington
- CTR fund from Indiana CTSI
- National Institute of Health [R03EB030331, DP2AI160242, U01DA056242]
- Indiana University Imaging Center [NIH1S10OD024988-01]
In this study, a microfluidics-based mini-tumor chip approach was developed to predict tumor responses to cancer immunotherapy. By generating mini-tumors on-chip and incorporating time-lapse live-cell imaging, the dynamic immune-tumor interactions and their responses to immunotherapy could be investigated within 36 hours.
Rationale: Predicting tumor responses to adjuvant therapies can potentially help guide treatment decisions and improve patient survival. Currently, tumor pathology, histology, and molecular profiles are being integrated into personalized profiles to guide therapeutic decisions. However, it remains a grand challenge to evaluate tumor responses to immunotherapy for personalized medicine. Methods: We present a microfluidics-based mini-tumor chip approach to predict tumor responses to cancer immunotherapy in a preclinical model. By uniformly infusing dissociated tumor cells into isolated microfluidic well-arrays, 960 mini-tumors could be uniformly generated on-chip, with each well representing the ex vivo tumor niche that preserves the original tumor cell composition and dynamic cell-cell interactions and autocrine/paracrine cytokines. Results: By incorporating time-lapse live-cell imaging, our mini-tumor chip allows the investigation of dynamic immune-tumor interactions as well as their responses to cancer immunotherapy (e.g., anti-PD1 treatment) in parallel within 36 hours. Additionally, by establishing orthotopic breast tumor models with constitutive differential PD-L1 expression levels, we showed that the on-chip interrogation of the primary tumor's responses to anti-PD1 as early as 10 days post tumor inoculation could predict the in vivo tumors' responses to anti-PD1 at the endpoint of day 24. We also demonstrated the application of this mini-tumor chip to interrogate on-chip responses of primary tumor cells isolated from primary human breast and renal tumor tissues. Conclusions: Our approach provides a simple, quick-turnaround solution to measure tumor responses to cancer immunotherapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据